STAT Plus: Mylan launches a low-cost biosimilar insulin, but experts say many patients may not save on costs

Amid a national outcry over the cost of insulin, one of the largest generic companies launched a biosimilar version at a wholesale price it claimed is 65% less than comparable treatments, although experts say the move is more likely to benefit payers than many patients.

Mylan (MYL) is marketing a long-acting version of the best-selling Lantus insulin — which the company named Semglee — for adults with Type 2 diabetes, and adults and children with Type 1 diabetes. But Mylan maintained the price for a package of 5 pens is equivalent to what Lantus sold for in 2007, and that a 10 ml vial is listed at the same price for which Lantus was sold a decade ago.

Continue to STAT Plus to read the full story…